ClinicalTrials.gov
public full text
Public Domain
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)#1150489
- Trial of Oxaloacetate in ALS#993645
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease#805144
- A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment#1128022
- Video-Based Proprioceptive Exercise Program in ALS#864081
Record · ID 1137320
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive